Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 55.90
-0.20 (-0.36%)
Dec 3, 2025, 1:35 PM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 14.8 billion as of December 3, 2025. Its market cap has increased by 45.99% in one year.
Market Cap
14.80B
Enterprise Value
14.96B
Revenue
224.83M
Ranking
n/a
PE Ratio
n/a
Stock Price
55.90
Market Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 14.80B, a decrease of -11.73%. That is a compound annual growth rate of -1.20%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 3, 2025 | 14.80B | 38.38% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | 9.89B | -9.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 243.49B |
| PharmaEssentia | 190.47B |
| Lotus Pharmaceutical | 82.05B |
| Bora Pharmaceuticals Co., LTD. | 67.80B |
| Lin BioScience | 35.74B |
| Lumosa Therapeutics | 34.03B |
| Oneness Biotech | 32.72B |
| Center Laboratories | 28.33B |